{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:55:41Z","timestamp":1781758541132,"version":"3.54.5"},"reference-count":194,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer is a heterogeneous disease comprising multiple molecular subtypes with distinct biological and clinical features. Among them, the basal-like subtype accounts for approximately 15\u201320% of cases and is associated with poor prognosis. Basal-like breast cancers (BLBC) share several histo-molecular characteristics with BRCA1-deficient tumors, including genomic instability and reduced BRCA1 expression beyond germline-mutated cases, suggesting potential alterations in homologous recombination (HR) DNA repair. These observations have led to the hypothesis that homologous recombination deficiency (HRD) may be enriched in a subset of BLBC. However, the extent, causes, and clinical implications of HRD in this subtype remain incompletely defined, as much of the available evidence is derived from triple-negative breast cancer (TNBC) cohorts, which only partially overlap with BLBC. In this review, we first summarize the transcriptomic definition of BLBC and its relationship to TNBC. We then provide a concise overview of current HRD detection methods, followed by a critical analysis of their application specifically to basal-like tumors. We next examine the molecular mechanisms that may contribute to HRD in BLBC, distinguishing well-supported alterations from emerging mechanisms. Finally, we discuss the therapeutic implications of HRD in BLBC, highlighting current limitations of clinical evidence and the challenges of translating a biologically defined subtype into a clinically actionable framework. Overall, while a BLBC-centered approach may offer a more biologically homogeneous context to study HRD, its clinical relevance remains to be established, and future studies specifically designed in molecularly defined cohorts will be required to clarify its diagnostic and therapeutic value.<\/jats:p>","DOI":"10.3389\/fonc.2026.1772663","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:39:15Z","timestamp":1781757555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Homologous recombination pathway alterations in basal-like breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Simon","family":"Aho","sequence":"first","affiliation":[{"name":"Department of medical oncology, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]},{"name":"Cancer Research Center of Lyon (CRCL), Inserm U1052-Centre National de la Recherche Scientifique (CNRS) UMR5286, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Guyot","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Lyon (CRCL), Inserm U1052-Centre National de la Recherche Scientifique (CNRS) UMR5286, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Maguer-Satta","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Lyon (CRCL), Inserm U1052-Centre National de la Recherche Scientifique (CNRS) UMR5286, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"S\u00f8rlie","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23518","article-title":"How basal are triple-negative breast cancers","volume":"123","author":"Bertucci","year":"2008","journal-title":"Int J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa052933","article-title":"Concordance among gene-expression\u2013based predictors for breast cancer","volume":"355","author":"Fan","year":"2006","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-04-2421","article-title":"Breast cancer molecular subtypes respond differently to preoperative chemotherapy","volume":"11","author":"Rouzier","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","article-title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"12","author":"Lehmann","year":"2021","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","article-title":"DNA double-strand break repair-pathway choice in somatic mammalian cells","volume":"20","author":"Scully","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nature05789","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209876","article-title":"Basal-like breast cancer and the BRCA1 phenotype","volume":"25","author":"Turner","year":"2006","journal-title":"Oncogene"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt306","article-title":"BRCAness: a deeper insight into basal-like breast tumors","volume":"24","author":"De Summa","year":"2013","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210014","article-title":"BRCA1 dysfunction in sporadic basal-like breast cancer","volume":"26","author":"Turner","year":"2007","journal-title":"Oncogene"},{"key":"B20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ijc.29829","article-title":"Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas: Genomic hallmarks of homologous recombination defect","volume":"138","author":"Mani\u00e9","year":"2016","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6548","DOI":"10.1038\/ncomms7548","article-title":"ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype","volume":"6","author":"Junankar","year":"2015","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13058-017-0861-2","article-title":"The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting","volume":"19","author":"Severson","year":"2017","journal-title":"Breast Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/gcc.20833","article-title":"Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors","volume":"50","author":"Joosse","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.01646-13","article-title":"BRCA1 pathway function in basal-like breast cancer cells","volume":"34","author":"Hill","year":"2014","journal-title":"Mol Cell Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-14-0201","article-title":"TGF\u03b2 induces \u201cBRCAness\u201d and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes","volume":"12","author":"Liu","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-025-00740-y","article-title":"Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics","volume":"13","author":"Witz","year":"2025","journal-title":"biomark Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx821","article-title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)","volume":"29","author":"Sharma","year":"2018","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05120-9","article-title":"Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC","volume":"174","author":"Imanishi","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/s41467-023-37537-2","article-title":"Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers","volume":"14","author":"Ter Brugge","year":"2023","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3934","article-title":"A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","article-title":"Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer","volume":"11","author":"Chopra","year":"2020","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0582-4","article-title":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","volume":"25","author":"Staaf","year":"2019","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-1912","article-title":"Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann\u2019s refined classification","volume":"24","author":"Echavarria","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.0085","article-title":"Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1 \/ 2 mutation\u2013associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105","volume":"33","author":"Telli","year":"2015","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3435-y","article-title":"Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)","volume":"151","author":"Kaklamani","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2064","article-title":"TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker","volume":"31","author":"Mayer","year":"2020","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response\u2014final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02151","article-title":"TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(18)30285-5","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy272.294","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00739-2","article-title":"Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy209","article-title":"Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2005.033043","article-title":"Basal-like breast carcinomas: clinical outcome and response to chemotherapy","volume":"59","author":"Banerjee","year":"2006","journal-title":"J Clin Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1038\/s41467-018-04334-1","article-title":"Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity","volume":"9","author":"Nguyen","year":"2018","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2174\/092986708785132834","article-title":"Laminin-332-integrin interaction: a target for cancer therapy","volume":"15","author":"Tsuruta","year":"2008","journal-title":"Curr Med Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.26.8.2877-2886.2006","article-title":"Multiple functions of the integrin\u00a0\u24236NL4 in epidermal homeostasis and tumorigenesis","volume":"26","author":"Wilhelmsen","year":"2006","journal-title":"Mol Cell Biol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nature04496","article-title":"Purification and unique properties of mammary epithelial stem cells","volume":"439","author":"Stingl","year":"2006","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800528","article-title":"Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma","volume":"19","author":"Livasy","year":"2006","journal-title":"Mod Pathol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711613105","article-title":"BRCA1 regulates human mammary stem\/progenitor cell fate","volume":"105","author":"Liu","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2000","article-title":"Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers","volume":"15","author":"Lim","year":"2009","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.07.010","article-title":"BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells","volume":"7","author":"Molyneux","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers2021040","article-title":"Biomarkers for basal-like breast cancer","volume":"2","author":"Choo","year":"2010","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2019.06.50","article-title":"Morphological and pathological features of basal-like breast cancer","volume":"8","author":"Botti","year":"2019","journal-title":"Transl Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/jci45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-0583","article-title":"New strategies for triple-negative breast cancer\u2014deciphering the heterogeneity","volume":"20","author":"Mayer","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0375-9","article-title":"Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial","volume":"31","author":"Jiang","year":"2021","journal-title":"Cell Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2741\/4230","article-title":"The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers","volume":"19","author":"Paul","year":"2014","journal-title":"Front Biosci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10147-017-1182-2","article-title":"BRCA1 gene: function and deficiency","volume":"23","author":"Takaoka","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503793102","article-title":"Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells","volume":"102","author":"Furuta","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/s41467-022-29885-2","article-title":"Pathogenic BRCA1 variants disrupt PLK1-regulation of mitotic spindle orientation","volume":"13","author":"He","year":"2022","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.12.007","article-title":"Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate","volume":"8","author":"Proia","year":"2011","journal-title":"Cell Stem Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaf5402","article-title":"A TGFb\u2013miR-182\u2013BRCA1 axis controls the mammary differentiation hierarchy","volume":"9","author":"Martinez-Ruiz","year":"2016","journal-title":"Sci Signal"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.05.038","article-title":"BRCA1\/FANCD2\/BRG1-driven DNA repair stabilizes the differentiation state of human mammary epithelial cells","volume":"63","author":"Wang","year":"2016","journal-title":"Mol Cell"},{"key":"B74","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1186\/bcr1636","article-title":"Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival","volume":"9","author":"Fulford","year":"2007","journal-title":"Breast Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-05-2281","article-title":"Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas","volume":"12","author":"Rodr\u00edguez-Pinilla","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.123","article-title":"Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast","volume":"23","author":"Marginean","year":"2010","journal-title":"Mod Pathol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00428-010-0988-3","article-title":"Immunophenotypic predictive profiling of BRCA1-associated breast cancer","volume":"458","author":"Domagala","year":"2011","journal-title":"Virchows Arch"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210975","article-title":"Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes","volume":"27","author":"Melchor","year":"2008","journal-title":"Oncogene"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-654","article-title":"BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations","volume":"10","author":"Holstege","year":"2010","journal-title":"BMC Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2007.10.011","article-title":"Expression of BRCA1 protein in breast cancer and its prognostic significance","volume":"39","author":"Rakha","year":"2008","journal-title":"Hum Pathol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw329","article-title":"Breast cancer survival of BRCA1\/BRCA2 mutation carriers in a hospital-based cohort of young women","volume":"109","author":"Schmidt","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"key":"B83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cpt.2025.06.001","article-title":"Survival outcomes in BRCA1 or BRCA2 mutation carriers and the influence of triple-negative breast cancer subtype","volume":"22","author":"Haque","year":"2018","journal-title":"Perm J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1097\/ogx.0b013e31824b70b7","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1186\/1897-4287-2-3-131","article-title":"The pathology of hereditary breast cancer","volume":"2","author":"Honrado","year":"","journal-title":"Hered Cancer Clin Pract"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0b013e31819c1c93","article-title":"Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers","volume":"33","author":"Collins","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-04-2424","article-title":"Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype","volume":"11","author":"Lakhani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg050","article-title":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","volume":"95","author":"Foulkes","year":"2003","journal-title":"CancerSpectrum Knowl Environ"},{"key":"B89","article-title":"Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations","volume":"57","author":"Tirkkonen","year":"1997","journal-title":"Cancer Res"},{"key":"B90","article-title":"Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors","volume":"62","author":"Wessels","year":"2002","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.10.009","article-title":"Genomic and transcriptional aberrations linked to breast cancer pathophysiologies","volume":"10","author":"Chin","year":"2006","journal-title":"Cancer Cell"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20366","article-title":"Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer","volume":"45","author":"Bergamaschi","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-08-1878","article-title":"Tiling path genomic profiling of grade 3 invasive ductal breast cancers","volume":"15","author":"Natrajan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2536","article-title":"Integrated profiling of basal and luminal breast cancers","volume":"67","author":"Ad\u00e9la\u00efde","year":"2007","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0475-x","article-title":"Association of BRCA1\/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","volume":"16","author":"Timms","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-018-0066-6","article-title":"Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer","volume":"4","author":"Sztupinszki","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0179-8","article-title":"Copy number signatures and mutational processes in ovarian carcinoma","volume":"50","author":"Macintyre","year":"2018","journal-title":"Nat Genet"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa261","article-title":"ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing","volume":"36","author":"Eeckhoutte","year":"2020","journal-title":"Bioinformatics"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-22-0590","article-title":"RNA-based classification of homologous recombination deficiency in racially diverse patients with breast cancer","volume":"31","author":"Walens","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B105","doi-asserted-by":"publisher","first-page":"R17","DOI":"10.1186\/bcr2486","article-title":"Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins","volume":"12","author":"Asakawa","year":"2010","journal-title":"Breast Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-1027","article-title":"A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer","volume":"16","author":"Graeser","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib monotherapy as primary treatment in unselected triple negative breast cancer","volume":"32","author":"Eikesdal","year":"2021","journal-title":"Ann Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-09-0149","article-title":"Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies","volume":"7","author":"Willers","year":"2009","journal-title":"Mol Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/path.4890","article-title":"Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer: Homologous recombination defective breast cancers","volume":"242","author":"Mutter","year":"2017","journal-title":"J Pathol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2017-0003","article-title":"Functional Ex Vivo assay to select homologous recombination\u2013deficient breast tumors for PARP inhibitor treatment","volume":"20","author":"Naipal","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1145\/1449913.1449929","article-title":"Functional Ex Vivo assay reveals homologous recombination deficiency in breast cancer beyond BRCA gene defects","volume":"24","author":"Meijer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809172","article-title":"A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo\u2010Bermejo","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.13.1748","article-title":"Basal-like breast cancer: a critical review","volume":"26","author":"Rakha","year":"2008","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.6660","article-title":"TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13073-025-01576-9","article-title":"Molecular profiling of the basal-like intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer","volume":"17","author":"Hohmann","year":"2025","journal-title":"Genome Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239197","article-title":"Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures","volume":"15","author":"Bodily","year":"2020","journal-title":"PloS One"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.8.4105","article-title":"BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination","volume":"6","author":"Cousineau","year":"2007","journal-title":"Cell Cycle"},{"key":"B120","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/gcc.20723","article-title":"Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency","volume":"49","author":"Rennstam","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110969108","article-title":"Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells","volume":"108","author":"Konishi","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"B122","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1038\/ncomms8505","article-title":"Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence","volume":"6","author":"Sedic","year":"2015","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26576","article-title":"Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer","volume":"118","author":"Hartman","year":"2012","journal-title":"Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/bd-2010-0306","article-title":"BRCA1\/2 mutations and triple negative breast cancers","volume":"32","author":"Peshkin","year":"2011","journal-title":"Breast Dis"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/humu.9308","article-title":"Novel somatic mutations in the BRCA1 gene in sporadic breast tumors","volume":"25","author":"Janatova","year":"2005","journal-title":"Hum Mutat"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4552-6","article-title":"BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation","volume":"167","author":"Brianese","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa175","article-title":"Molecular features and functional implications of germline variants in triple-negative breast cancer","volume":"113","author":"Ma","year":"2021","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B131","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12885-018-4029-y","article-title":"Prevalence of pathogenic BRCA1\/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history","volume":"18","author":"Engel","year":"2018","journal-title":"BMC Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.020669","article-title":"The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype","volume":"15","author":"Heikkinen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20822","article-title":"BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer","volume":"49","author":"Sabatier","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-004-7603-8","article-title":"BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles","volume":"91","author":"Matros","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-012-1286-z","article-title":"BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression","volume":"461","author":"Bal","year":"2012","journal-title":"Virchows Arch"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/s0962-8924(03)00147-8","article-title":"Id proteins in development, cell cycle and cancer","volume":"13","author":"Ruzinova","year":"2003","journal-title":"Trends Cell Biol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.131589","article-title":"Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach","volume":"98","author":"Beger","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.5.5.2597","article-title":"Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer","volume":"5","author":"Rold\u00e1n","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"B140","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-015-3648-0","article-title":"Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer","volume":"155","author":"Branham","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B141","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10549-012-2070-0","article-title":"Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation","volume":"135","author":"Wen","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/his.12801","article-title":"Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1\/2 proteins in triple-negative breast cancer, adversely affects survival","volume":"68","author":"Thike","year":"2016","journal-title":"Histopathology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13058-020-01306-6","article-title":"Proteogenomic analysis of inhibitor of differentiation 4 (ID4) in basal-like breast cancer","volume":"22","author":"Baker","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.880643","article-title":"Homologous recombination deficiency in ovarian, breast, colorectal, pancreatic, non-small cell lung and prostate cancers, and the mechanisms of resistance to PARP inhibitors","volume":"12","author":"Mekonnen","year":"2022","journal-title":"Front Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9766-6","article-title":"Estrogen receptor \u03b1, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers","volume":"111","author":"Wei","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(03)00930-9","article-title":"EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer","volume":"115","author":"Hughes-Davies","year":"2003","journal-title":"Cell"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1380-y","article-title":"EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry","volume":"127","author":"Bane","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-03-0410","article-title":"Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome","volume":"10","author":"Rodriguez","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq468","article-title":"Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy","volume":"22","author":"Lips","year":"2011","journal-title":"Ann Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s00438-011-0612-5","article-title":"EMSY overexpression disrupts the BRCA2\/RAD51 pathway in the DNA-damage response: implications for chromosomal instability\/recombination syndromes as checkpoint diseases","volume":"285","author":"Cousineau","year":"2011","journal-title":"Mol Genet Genomics"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1817-3","article-title":"Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours","volume":"133","author":"Holm","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.4.1783","article-title":"Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas","volume":"15","author":"Madjd","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3976-8","article-title":"EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations","volume":"160","author":"Navazio","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/path.1710","article-title":"The pathophysiology ofHOX genes and their role in cancer","volume":"205","author":"Grier","year":"2005","journal-title":"J Pathol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1172\/jci39534","article-title":"HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype","volume":"120","author":"Gilbert","year":"2010","journal-title":"J Clin Invest"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.23.7.2225-2238.2003","article-title":"Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma","volume":"23","author":"Baldassarre","year":"2003","journal-title":"Mol Cell Biol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201100136","article-title":"Down\u2010regulation of BRCA1 expression by miR\u2010146a and miR\u2010146b\u20105p in triple negative sporadic breast cancers","volume":"3","author":"Garcia","year":"2011","journal-title":"EMBO Mol Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-015-0239-3","article-title":"Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers","volume":"38","author":"Fkih","year":"2015","journal-title":"Cell Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgn172","article-title":"A functional polymorphism in the miR-146a gene and age of familial breast\/ovarian cancer diagnosis","volume":"29","author":"Shen","year":"2008","journal-title":"Carcinogenesis"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgq184","article-title":"Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1\/BRCA2-negative familial breast and ovarian cancer patients","volume":"31","author":"Pastrello","year":"2010","journal-title":"Carcinogenesis"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.12.005","article-title":"miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors","volume":"41","author":"Moskwa","year":"2011","journal-title":"Mol Cell"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2011.01.005","article-title":"A new role for miR-182 in DNA repair","volume":"41","author":"Yao","year":"2011","journal-title":"Mol Cell"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24008","article-title":"Novel genetic variants in microRNA genes and familial breast cancer","volume":"124","author":"Shen","year":"2009","journal-title":"Int J Cancer"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.30","article-title":"Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer","volume":"5","author":"De Summa","year":"2014","journal-title":"Cell Death Dis"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0435-5","article-title":"miR-638 mediated regulation of BRCA1affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer","volume":"16","author":"Tan","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2015.00242","article-title":"Post-transcriptional regulation of BRCA1 through its coding sequence by the miR-15\/107 group of miRNAs","volume":"6","author":"Quann","year":"2015","journal-title":"Front Genet"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-1800","article-title":"Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer","volume":"17","author":"Li","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjr046","article-title":"Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair","volume":"4","author":"Song","year":"2012","journal-title":"J Mol Cell Biol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3616-8","article-title":"SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer","volume":"154","author":"Llombart-Cussac","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B170","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann Oncol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05259-z","article-title":"Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)","volume":"176","author":"Fontaine","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B172","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/nejmoa1513749","article-title":"Adaptive randomization of Veliparib\u2013Carboplatin treatment in breast cancer","volume":"375","author":"Rugo","year":"2016","journal-title":"N Engl J Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01304","article-title":"Neoadjuvant Talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant","volume":"38","author":"Litton","year":"2020","journal-title":"J Clin Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2105215","article-title":"Adjuvant Olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.22.4725","article-title":"Efficacy of neoadjuvant cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J Clin Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13574","article-title":"Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with triple-negative breast cancer","volume":"26","author":"Yuan","year":"2021","journal-title":"Oncologist"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3646","article-title":"Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I\u2013III triple-negative breast cancer (NeoSTOP)","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03292","article-title":"TBCRC 031: Randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial)","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3100-x","article-title":"Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients","volume":"147","author":"Byrski","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B180","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1158\/1078-0432.ccr-22-0482","article-title":"De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial","volume":"28","author":"Gluz","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B181","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/jco.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0335-x","article-title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","volume":"34","author":"Kummar","year":"2016","journal-title":"Invest New Drugs"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"2","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30447-2","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Di\u00e9ras","year":"2020","journal-title":"Lancet Oncol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy201","article-title":"nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial","volume":"29","author":"Yardley","year":"2018","journal-title":"Ann Oncol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O\u2019Shaughnessy","year":"2014","journal-title":"J Clin Oncol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab Govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2508959","article-title":"Sacituzumab Govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.03.008","article-title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","author":"Dent","year":"2026","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9632-6","article-title":"Epidemiology of basal-like breast cancer","volume":"109","author":"Millikan","year":"2008"},{"key":"B194","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1772663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:39:20Z","timestamp":1781757560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1772663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":194,"alternative-id":["10.3389\/fonc.2026.1772663"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1772663","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1772663"}}